Cargando…
Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis
This meta-analysis has been conducted to compare ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe Crohn's disease (CD). The current meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Rev...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226155/ https://www.ncbi.nlm.nih.gov/pubmed/37255887 http://dx.doi.org/10.7759/cureus.38277 |
_version_ | 1785050518082551808 |
---|---|
author | Chenna, Venkata Sai Harshabhargav Nagi, Talwinder K Suarez, Zoilo K Hernandez, Oscar L Nageye, Maymona E Reyaz, Nafisa Reyaz, Ibrahim Ali, Neelum |
author_facet | Chenna, Venkata Sai Harshabhargav Nagi, Talwinder K Suarez, Zoilo K Hernandez, Oscar L Nageye, Maymona E Reyaz, Nafisa Reyaz, Ibrahim Ali, Neelum |
author_sort | Chenna, Venkata Sai Harshabhargav |
collection | PubMed |
description | This meta-analysis has been conducted to compare ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe Crohn's disease (CD). The current meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two investigators independently searched online databases including PubMed, Cumulated Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Library for relevant articles published up to April 2023. The initial search terms were “ustekinumab,” “adalimumab,” and “Crohn’s disease". Three studies (with a total of 612 patients) were included in the present meta-analysis. We did not find any significant difference in clinical remission (OR: 1.31, 95% CI: 0.68-2.52), clinical response (OR: 1.39, 95% CI: 0.39-4.91), endoscopic remission (OR: 1.56, 95% CI: 0.66-3.64), and steroid-free remission (OR: 0.98, 95% CI: 0.67-1.42) between patients who received ustekinumab and patients who received adalimumab. In conclusion, this meta-analysis provides valuable insights into the efficacy and safety of ustekinumab and adalimumab in the treatment of moderate to severe CD. Our findings indicate that both drugs have similar effectiveness in achieving clinical remission, clinical response, radiological remission and steroid-free remission. |
format | Online Article Text |
id | pubmed-10226155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-102261552023-05-30 Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis Chenna, Venkata Sai Harshabhargav Nagi, Talwinder K Suarez, Zoilo K Hernandez, Oscar L Nageye, Maymona E Reyaz, Nafisa Reyaz, Ibrahim Ali, Neelum Cureus Family/General Practice This meta-analysis has been conducted to compare ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe Crohn's disease (CD). The current meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two investigators independently searched online databases including PubMed, Cumulated Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Library for relevant articles published up to April 2023. The initial search terms were “ustekinumab,” “adalimumab,” and “Crohn’s disease". Three studies (with a total of 612 patients) were included in the present meta-analysis. We did not find any significant difference in clinical remission (OR: 1.31, 95% CI: 0.68-2.52), clinical response (OR: 1.39, 95% CI: 0.39-4.91), endoscopic remission (OR: 1.56, 95% CI: 0.66-3.64), and steroid-free remission (OR: 0.98, 95% CI: 0.67-1.42) between patients who received ustekinumab and patients who received adalimumab. In conclusion, this meta-analysis provides valuable insights into the efficacy and safety of ustekinumab and adalimumab in the treatment of moderate to severe CD. Our findings indicate that both drugs have similar effectiveness in achieving clinical remission, clinical response, radiological remission and steroid-free remission. Cureus 2023-04-29 /pmc/articles/PMC10226155/ /pubmed/37255887 http://dx.doi.org/10.7759/cureus.38277 Text en Copyright © 2023, Chenna et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Family/General Practice Chenna, Venkata Sai Harshabhargav Nagi, Talwinder K Suarez, Zoilo K Hernandez, Oscar L Nageye, Maymona E Reyaz, Nafisa Reyaz, Ibrahim Ali, Neelum Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis |
title | Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis |
title_full | Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis |
title_fullStr | Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis |
title_short | Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis |
title_sort | comparison of effectiveness and safety of ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe crohn's disease: a systematic review and meta-analysis |
topic | Family/General Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226155/ https://www.ncbi.nlm.nih.gov/pubmed/37255887 http://dx.doi.org/10.7759/cureus.38277 |
work_keys_str_mv | AT chennavenkatasaiharshabhargav comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis AT nagitalwinderk comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis AT suarezzoilok comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis AT hernandezoscarl comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis AT nageyemaymonae comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis AT reyaznafisa comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis AT reyazibrahim comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis AT alineelum comparisonofeffectivenessandsafetyofustekinumabandadalimumabasinductionormaintenancetherapyinpatientswithmoderatetoseverecrohnsdiseaseasystematicreviewandmetaanalysis |